RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity

RUNX1/AML1 is among the most commonly mutated genes in human leukemia. Haploinsufficiency of RUNX1 causes familial platelet disorder with predisposition to myeloid malignancies (FPD/MM). However, the molecular mechanism of FPD/MM remains unknown. Here we show that murine Runx1+/− hematopoietic cells are hypersensitive to granulocyte colony-stimulating factor (G-CSF), leading to enhanced expansion and mobilization of stem/progenitor cells and myeloid differentiation block. Upon G-CSF stimulation, Runx1+/− cells exhibited a more pronounced phosphorylation of STAT3 as compared with Runx1+/+ cells, which may be due to reduced expression of Pias3, a key negative regulator of STAT3 signaling, and reduced physical sequestration of STAT3 by RUNX1. Most importantly, blood cells from a FPD patient with RUNX1 mutation exhibited similar G-CSF hypersensitivity. Taken together, Runx1 haploinsufficiency appears to predispose FPD patients to MM by expanding the pool of stem/progenitor cells and blocking myeloid differentiation in response to G-CSF.


INTRODUCTION
RUNX1 is one of the most frequently mutated genes in human leukemia. Approximately 30% of acute leukemias carry RUNX1 genetic alterations such as chromosomal translocation, point mutations and deletions. 1,2 A germline mutation of RUNX1 is causally linked to familial platelet disorder with predisposition to myeloid malignancies (FPD/MM), a rare autosomal dominant disorder characterized by modest thrombocytopenia and defective platelet function, with 35% lifetime risk of developing leukemia. [3][4][5][6] To date,~30 families have been reported. 7 Most of the RUNX1 mutations identified in these patients concentrate within the Runt domain and disrupt the DNA binding and β heterodimerization capabilities. 1 In some cases, mutations are also found in the carboxyl terminus, abrogating the transactivation domain and resulting in formation of dominant negative forms of RUNX1. 4 Runx1 is well established as a master regulator of hematopoiesis. Runx1 −/− murine embryos die at embryonic day 12.5 due to hemorrhage in the central nervous system and inability to generate hematopoietic stem cells (HSCs). 8,9 Inactivation of Runx1 at the adult stage using Runx1 conditional knockout mice results in expansion and subsequent exhaustion of hematopoietic stem and progenitor cells (HSPCs). 10,11 Runx1 deficiency is insufficient for leukemogenesis and requires the accumulation of additional mutations for transformation. 11 Runx1 haploinsufficiency is also insufficient for leukemogenesis, although mild phenotypes such as reduced platelet counts and elevated hematopoietic progenitor counts were observed in Runx1 +/ − mice, which are genetically identical to FPD patients. 12,13 It remains unclear how RUNX1 haploinsufficiency promotes leukemogenesis in FPD patients.
HSC behaviors such as self-renewal, proliferation and mobilization are tightly orchestrated by cell intrinsic and extrinsic factors, the latter of which includes secreted factors and cell-cell interactions within the bone marrow (BM) niche. [14][15][16] Granulocyte colony-stimulating factor (G-CSF) is a potent cytokine that induces HSPC proliferation, mobilization and promotion of granulopoiesis. 17,18 Many infections trigger stressed granulopoiesis through the production of G-CSF to augment granulocyte differentiation. G-CSF is clinically used to mobilize and collect HSCs for peripheral blood stem cell transplantation. 19 G-CSF also alleviates severe neutropenia in severe congenital neutropenia patients. 20 Recently, there has been growing evidence that suggests an intimate link between RUNX1 and G-CSF signaling. Mutations in RUNX1 and G-CSF receptor (CSF3R) genes were concurrently found in severe congenital neutropenia patients who developed acute myeloid leukemia. 21 Treatment with G-CSF and the loss of RUNX1 enhance the detachment of long-term HSCs from the niche and increase the frequency of short-term HSCs. 16 We recently reported that deficiency of Runx3, a closely related member of RUNX family, also results in G-CSF hypersensitivity. 22 To better understand how Runx1 haploinsufficiency contributes to leukemogenesis, the steady-state hematopoiesis and cytokine responses of Runx1 +/ − mice were carefully examined. Runx1 +/ − mice exhibited G-CSF hypersensitivity as evidenced by HSPC expansion and mobilization to the periphery, as well as myeloid differentiation block. Importantly, FPD patient-derived peripheral blood mononuclear cells harboring a RUNX1 point mutation demonstrated similar G-CSF hypersensitivity when compared with healthy donor cells. These results suggest that Runx1 haploinsufficiency can increase the pool of immature progenitor cells, thereby increasing the probability of acquiring cooperative mutations for leukemic transformation.

Mice and G-CSF stimulation
Runx1 +/ − mice were generated by Okada et al. 23 and maintained in the C57BL/6 background. Experiments were carried out using 6 to 8-week-old littermates. For in vivo G-CSF administration, mice were subcutaneously injected with 250 μg/kg/day murine G-CSF or phosphate-buffered saline daily for three consecutive days. Peripheral blood (PB) was obtained via retro-orbital bleeding. Mice were killed at 24 or 72 h after the final injection. BM cells were harvested by flushing femurs and tibias in ice-cold phosphate-buffered saline and incubated with red blood cell lysis buffer. All experimental procedures were approved by Institutional Animal Care and Use Committee (IACUC).
FPD patient PB samples from subjects were collected after obtaining written informed consent. The study was conducted with approval from the internal review board of Keio University School of Medicine, Tokyo, Japan and conformed to the principles outlined in the Declaration of Helsinki for use of human tissue or subjects.

Luciferase assay
The luciferase reporter plasmid pGL3-CXCR4-luc, 24 pGL3-PIAS3-luc and effector RUNX1 plasmids were transfected into HL-60 cells using FuGENE 6 (Promega, Madison, WI, USA). Equal amounts of DNA were transfected by supplementing appropriate amounts of the backbone pEF plasmid. Forty-eight hours after transfection, cells were lysed with 1 × passive lysis buffer, and the luciferase assay was performed using the Dual-Luciferase Reporter Assay Kit (Promega

Statistical analysis
Differences between samples were evaluated by two-tailed Student's t-test. All values are expressed as mean ± s.d. unless otherwise stated. P-valueso0.05 were considered statistically significant.

Runx1 +/ − BM cells exhibit cytokine sensitivity in vitro
To investigate the impact of RUNX1 haploinsufficiency on hematopoiesis and leukemogenesis in FPD/MM patients, we used mice that are heterozygous for the Runx1 null mutation (Runx1 +/ − ). Complete blood count analysis of 6-8-week-old Runx1 +/ − mice showed normal frequency of white blood cells and hemoglobin, but a significant reduction in platelet counts (Supplementary Figure 1A). Runx1 +/ − mice did not exhibit major differences in the percentages of Mac-1 + Gr-1 + granulocytes, B220 + CD19 + B cells and CD3 + T cells within the BM, compared with Runx1 +/+ mice (Supplementary Figure 1B). Despite Runx1 +/ − mice having reduced platelet counts, CD41 + CD61 + megakaryocytes were modestly increased in the BM (Supplementary Figure 1B), probably due to blockage in megakaryocyte differentiation. The spleen of Runx1 +/ − mice showed increased granulocytes but decreased T-cell frequencies (Supplementary Figure 1C). Further examination of the HSPCs and myeloid progenitor compartments in the BM showed that the cKit + Sca-1 + Lin − (KSL) and cKit + Sca-1 -Lin − (KL) fractions were comparable between Runx1 +/+ and Runx1 +/ − mice (Supplementary Figure 1D). However, higher numbers of KSL and KL cells were consistently detected in the spleen of Runx1 +/ − mice (Supplementary Figure 1E). As compared with previous reports, which described HSPC expansion, lymphopenia and thrombocytopenia in Runx1 conditional knockout mice, 10,11 Runx1 +/ − mice display weaker hematopoietic phenotypes. Importantly, the reduction in platelet count of Runx1 +/ − mice mimics the mild thrombocytopenia observed in FPD patients.
We next investigated cytokine sensitivity of Runx1 +/ − cells. Whole-BM cells from Runx1 +/+ and Runx1 +/ − mice were cultured in methylcellulose supplemented with a single factor chosen from a panel of cytokines: IL-3, IL-6, G-CSF, granulocyte-macrophage CSF and stem cell factor. Runx1 +/ − BM cells formed twice the number of colonies of wild-type cells after stimulation with IL-6 and G-CSF, and to a lesser extent in the presence of IL-3 and granulocyte-macrophage CSF (Figure 1a). These observations indicate that Runx1 +/ − status enhances multiple cytokine responses. G-CSF and IL-6 share a common downstream signaling molecule, STAT3. Owing to the known association between Runx1 and G-CSF in MM stated earlier, we chose to focus our experiments on G-CSF. In vitro stimulation of whole-BM cells with increasing dosage of G-CSF revealed that Runx1 +/ − BM cells formed significantly more colonies at concentrations of 10 and 100 ng/ml G-CSF (Figure 1b). To further identify the exact cellular population that is hyper-responsive to G-CSF, KSL and the various myeloid progenitors were sorted and treated with G-CSF in vitro. The colony-forming capacity of the KSL compartment of Runx1 +/ − mice showed the greatest difference when compared with littermate control, though this trend of G-CSF hypersensitivity was also observed in other myeloid progenitor compartments ( Figure 1c). The results from the in vitro colony-forming assays demonstrate that Runx1 haploinsufficiency promotes hypersensitivity to G-CSF of HSPCs. As G-CSF is a potent agent for mobilization of HSPCs, we compared the HSPC mobilization between Runx1 +/+ and Runx1 +/ − mice after G-CSF administration. When assessed at 24 and 72 h after the final G-CSF injection (days 4 and 7, respectively), PB cells from Runx1 +/ − mice formed more colonies than Runx1 +/+ mice in methylcellulose culture (Figure 2d), reflecting an elevated number of migrating HSPCs in Runx1 +/ − mice. In agreement with the PB CFU-C assay, significantly higher frequencies of KSL and KL cells were also detected in the spleen of G-CSF-treated Runx1 +/ − mice compared with those of Runx1 +/+ mice ( Figure 2e). Moreover, G-CSF treatment also resulted in a significant increase in splenic GMP frequency in Runx1 +/ − mice as compared with treated control mice (Figure 2f). These results clearly demonstrate that Runx1 +/ − HSPCs were more responsive to G-CSF and readily mobilized out of the BM.
To determine the effect of G-CSF on the differentiation of myeloid cells, we assessed the frequencies of Mac-1 hi Gr-1 hi and Mac-1 hi Gr-1 int granulocytes in the BM. G-CSF treatment of Runx1 +/+ mice showed a fourfold increase in the percentage of Mac-1 hi Gr-1 int granulocytes in the BM as compared with phosphate-buffered saline-treated control mice (Figure 2g). Interestingly, G-CSF treatment of Runx1 +/ − mice resulted in eightfold increase in the Mac-1 hi Gr-1 int fraction, accompanied by modest decrease in Mac-1 hi Gr-1 hi granulocytes ( Figure 2g). These results suggest that Runx1 haploinsufficiency impedes G-CSF-induced granulopoiesis, which leads to accumulation of both GMP and Mac-1 hi Gr-1 int granulocytes in the BM.
To further evaluate whether Runx1 +/ − mice also show prolonged response to G-CSF, we performed similar analysis 72 h after the final G-CSF administration. The frequencies of the various HSPC and myeloid progenitor fractions in the BM were also comparable (Supplementary Figures 3A-C). However, the frequencies of splenic KSL and KL cells in Runx1 +/ − mice remained significantly higher than those in Runx1 +/+ mice and steady-state Runx1 +/ − mice (Supplementary Figure 3D). The increase in GMPs in the spleen of Runx1 +/ − mice was also observed like steady-state Runx1 +/ − mice (Supplementary Figure 3E), whereas the percentages of Mac-1 hi Gr-1 hi and Mac-1 hi Gr-1 int granulocytes in the BM were almost comparable between Runx1 +/ − and Runx1 +/+ mice (Supplementary Figure 3F). These results suggest that Runx1 haploinsufficiency causes G-CSF hypersensitivity, resulting in prolonged mobilization of HSPCs. RUNX1 negatively regulates STAT3 activation G-CSF binds to its receptor and rapidly induces the phosphorylation of STAT3, which then translocates to the nucleus to induce gene transcription. We therefore assessed whether G-CSF hypersensitivity of Runx1 +/ − mice was due to an increased phosphorylation of STAT3 at tyrosine 705 (p-STAT3) compared with Runx1 +/+ mice. After 15 and 60 min of G-CSF treatment, p-STAT3 was significantly higher in whole-BM of Runx1 +/ − mice than Runx1 +/+ mice (Figure 3a). The magnitude of p-STAT3 activation among HSPCs and myeloid progenitor cells of Runx1 +/+ and Runx1 +/ − mice was also analyzed by comparing the mean fluorescence intensity by Phosflow analysis. Induction of p-STAT3 was also significantly higher in the KSL and KL compartments of Runx1 +/ − mice than that of their Runx1 +/+ counterparts (Figure 3b). Elevated STAT3 activation was not due to increased expression of Csf3r as the expression of Csf3r mRNA was indistinguishable in the Runx1 +/ − and Runx1 +/+ KSL fractions (Figure 3c).
To further support the notion that RUNX1 negatively regulate STAT3 activation, we tested the ability of RUNX1 to reduce G-CSFinduced STAT3 phosphorylation in 32Dcl3 myeloid cells. Overexpression of RUNX1 in 32Dcl3 cells resulted in a significant  Data represent mean ± s.d.. Three independent experiments were performed. Asterisks represent significant differences (*P o0.05, **P o0.01, ***P o0.001 and two-tailed Student's t-test).
Runx1 haploinsufficiency and G-CSF hypersensitivity DWL Chin et al families of proteins are well-established negative regulators of STAT signaling. Therefore, we examined if these genes were differentially expressed in the KSL compartment of Runx1 +/+ and Runx1 +/ − mice. Expression of Pias3, a specific negative regulator of STAT3 was significantly reduced in the BM KSL cells of Runx1 +/ − mice (Figure 4a). This reduced expression of Pias3 was also observed in the spleen KSL cells from Runx1 +/ − mice (Figure 4b). These results suggest that G-CSF hypersensitivity in Runx1 +/ − HSPCs may be due to the reduced expression of Pias3. Surprisingly the expression of another feedback regulator, Socs3, was conversely upregulated in Runx1 +/ − BM KSL cells; however, this upregulation of Socs3 expression was not detected in the spleen KSL cells of Runx1 +/ − mice (Figure 4b). It is known that secretion of G-CSF in the BM is much higher than that in the spleen. 25 Therefore, our observation of Socs3 upregulation in Runx1 +/ − BM is probably an indication of active STAT3 signaling, but not a direct consequence of Runx1 +/ − status.
The reduced expression of Pias3 in Runx1 +/ − KSL cells prompted us to investigate if Runx1 is a direct regulator of Pias3 expression. Examination of publicly available chromatin immunoprecipitation-sequencing data set showed enrichment in the binding of RUNX1 at the promoter region of PIAS3 in both human CD34 + megakaryocytes 26 (Figure 4c) and 12-O-tetradecanoylphorbol-13-actate-induced murine L8057 cells 27 (data not shown). Motif search analysis revealed that 3 RUNX1-binding consensus sequences were found within close proximity in the human PIAS3 promoter. To ascertain the role of RUNX1 in the regulation of PIAS3 expression, the − 1.2-Kb promoter region covering these 3 RUNX1-binding sites were cloned upstream of a luciferase reporter. Transfection of RUNX1 and CBFβ strongly induced luciferase expression (Figure 4d). We tested two RUNX1 mutants, which were previously described in FPD/MM pedigrees, 3,4 R174Q and Y260X, for their ability to induce PIAS3 expression. Both R174Q and Y260X mutants were unable to transactivate luciferase (Figure 4d). Together, these results indicate that RUNX1 positively regulate the expression of PIAS3 in a DNAbinding dependent manner.
One of the most prominent phenotypes observed in Runx1 +/ − mice after G-CSF stimulation was the enhanced mobilization of HSPCs. CXCR4 is known to be a RUNX1 target gene and directly influences HSC retention in BM. Although RUNX1 transactivated the − 2.6-KB promoter of human CXCR4, both mutants of RUNX1 (R174Q and Y260X) were unable to do so (Figure 4e). Cxcr4 expression was marginally reduced at the mRNA level when comparing phosphate-buffered saline-treated Runx1 +/ − KSL cells to Runx1 +/+ KSL cells (Figure 4f). Treatment with G-CSF resulted in a further reduction of the mRNA expression of Cxcr4 in Runx1 +/ − KSL cells (Figure 4f). This G-CSF-mediated suppression of Cxcr4 expression may serve to augment the egress of KSL cells from the BM in Runx1 +/ − mice.
RUNX1 attenuates STAT3 signaling by physical interaction Several groups have reported that STAT family proteins interact with RUNX proteins to attenuate their transcriptional function. 28,29 As such, we evaluated if RUNX1 is able to modulate STAT3 activation via physical interaction. The physical interaction between RUNX1 and STAT3 was tested using GFP-pulldown assay. RUNX1 was co-immunoprecipitated with exogenous GFP-tagged STAT3 (Figure 5a). Similarly, STAT3 was co-immunoprecipitated together with exogenous GFP-tagged RUNX1 (Figure 5b). Endogenous interaction between RUNX1 and STAT3 was also confirmed in Jurkat cells (Figure 5c). These results demonstrate that RUNX1 physically interacts with STAT3. We further used various RUNX1 and STAT3 deletion constructs to determine the interacting domains of RUNX1 and STAT3 (Figure 5d). Unlike full-length RUNX1, RUNX1 with deleted Runt domain (RUNX1 ΔRD ), RUNX1 Δ189 and RUNX1 Δ243 failed to interact with STAT3, whereas Runt domain alone was successfully coimmunoprecipitated with STAT3 ( Figure 5e). Therefore, RUNX1 interacts with STAT3 predominantly via the Runt domain. In a reciprocal experiment, STAT3/RUNX1 interaction was preserved in deletion mutants STAT3 1-514 and STAT3 1-600 , but disrupted in the STAT3 1-309 mutant (Figure 5f). Hence the DNA-binding domain of STAT3 is likely to be essential for the interaction with RUNX1. We also tested if the various RUNX1 mutants have the ability to attenuate p-STAT3. Only full-length RUNX1 and RUNX1 ΔN45 mutant retained the ability to attenuate the phosphorylation of STAT3, whereas all non-interacting mutants failed to do so (Figure 5g).
We next tested the ability of FPD-related RUNX1 point mutants to associate with STAT3 using similar co-immunoprecipitation experiments. Both R174Q and Y260X mutants were able to interact with exogenous STAT3 (Figure 5h). However, both R174Q and Y260X were unable to attenuate STAT3 phosphorylation after treatment with oncostatin-M ( Figure 5i). Our data suggest that although the Runt domain is sufficient for STAT3 interaction, both the Runt domain and carboxyl terminus of RUNX1 are required to exert negative regulation on STAT3.
FPD patient with RUNX1 point mutation displays G-CSF hypersensitivity Finally, we sought to test whether FPD patients harboring RUNX1 point mutations present similar G-CSF hypersensitivity like the RUNX1 +/ − mice. PB mononuclear cells derived from a FPD patient with a RUNX1 G143W mutation were able to form two-to threefold more colonies than healthy volunteers with wild-type RUNX1 in increasing doses of G-CSF (Figure 6a). In addition, morphological analysis of the colonies revealed that the colonies from the FPD patient were larger in size compared with healthy volunteers, suggesting that the proliferation rate of these RUNX1 mutant cells were increased (Figure 6b). Consistent with the observations in Runx1 +/ − mice, RUNX1 haploinsufficiency in the FPD patient also resulted in similar G-CSF hypersensitivity.

DISCUSSION
In this study, we show that Runx1 haploinsufficiency causes G-CSF hypersensitivity that manifests in two major phenotypes: (1) expansion and mobilization of HSPCs and (2) differentiation block in G-CSF-induced granulopoiesis. In response to G-CSF, Runx1 +/ − KSL cells sustained greater activation of STAT3 than Runx1 +/+ KSL cells. Our data depicts a model whereby RUNX1 exerts a negative regulation on STAT3 signaling in both transcriptional and non-transcriptional manners (Figure 6c, left). Our model shows that RUNX1 transcriptionally regulates PIAS3 and physically interacts with STAT3 to inhibit its function. The combined influence of these regulations ensures proper control of gene expression for HSPC proliferation, migration and differentiation. RUNX1 alterations in FPD patients, such as RUNX1 +/ − (Figure 6c, middle) or point mutants (Figure 6c, right), may result in weakened suppression of STAT3 signaling, and consequently aberrant HSPC expansion and delayed myeloid differentiation.
Recently, the Encyclopedia of DNA Elements (ENCODE) project reported a significant overrepresentation of the enrichment of RUNX1/STAT1/STAT3-binding motifs within the regulatory elements. 30 Coexistence of RUNX1− and STAT3-binding motifs in close proximity within the regulatory elements of various genes were reported to permit positive cooperative effects in the control of gene expression. 31,32 Such synergism between RUNX1 and STAT3 appears to be highly relevant in the context of several epithelial carcinomas. 33,34 Scheitz et al. 34 demonstrated that RUNX1 promotes STAT3 signaling via suppression of SOCS3 and SOCS4 expression. The loss of RUNX1 resulted in a reduction of STAT3 signaling and prevented the initiation and maintenance of epithelial tumors. In contrast, RUNX and STAT family proteins were shown to physically interact and mutually inhibit their own transcriptional function. 28,29,35 Although our data show that RUNX1 suppresses STAT3 signaling induced by G-CSF in the context of HSPCs, we do not deny the possibility that synergism between RUXN1 and STAT3 is also important. The net-effect of positive and negative regulations by RUNX1 will influence the eventual activation of G-CSF-induced gene expression programs.
We report that Runx1 +/ − mice showed G-CSF hypersensitivity due to insufficient sequestration of STAT3 by RUNX1. Importantly, an intact Runt domain is essential for RUNX1 to inhibit the transcriptional function of STAT3. In previous studies, both Stat1 and Stat3 were reported to interact and sequester Runx2 in the cytoplasm. 29,35 Stat5 was further shown to interact and attenuate the function of all members of RUNX transcription factors. 28 Taken together, all members of RUNX and STAT family transcription factors interact and mutually moderate the transcriptional activity of each other. The Runt domain is highly conserved across the different RUNX family members; thus RUNX2 and RUNX3 are likely to use Runt domain to interact with STAT family proteins. Runx3 conditional knockout mice also showed similar G-CSF hypersensitivity. 22 Therefore it strongly suggests that RUNX family proteins function as negative regulators of STAT signaling by physical interaction.
RUNX1 haploinsufficiency may result in exaggerated cytokine responses during infection, a short period of time when endogenous level of G-CSF and other cytokines can be greatly elevated for emergency granulopoiesis. 36 RUNX1 haploinsufficient individuals may experience minor granulocyte differentiation blockage and accumulate HSPCs in the spleen and PB over an extended period of time. Of the many progenitor populations, the most prominently expanded population in Runx1 +/ − mice, namely GMPs, have been regarded as candidate targets for oncogenic transformation in leukemia. 37 Furthermore, GMPs were efficiently transformed into leukemia-initiating cells by retroviral transduction of MLL-AF9. 38 Therefore, the sustained expansion of preleukemic GMPs in FPD patients may greatly elevate the likelihood of acquiring cooperating mutations to develop fullblown leukemia. As FPD/MM patients exhibit clinical heterogeneity in both the severity of platelet defects and age of leukemia onset, 39 extensive variability in the age of leukemia onset can be explained by the time at which the cooperating mutation was acquired and the severity of these cooperative hits. Mutations in RUNX1 are also considered to be initiating event for onset of various sporadic hematological malignancies such as myelodysplastic syndrome or chronic myelomonocytic leukemia.
We speculate that G-CSF-induced preleukemic GMPs expansion may also contribute to the leukemogenesis of these diseases.
FPD has been reported to be under-diagnosed due to the large variation in the severity of platelet defects. RUNX1 mutation   39 Furthermore, mutations in the RUNX1 coding regions are not the only scenario whereby RUNX1 haploinsufficiency can occur. A significant number of FPD pedigrees did not show mutation in the RUNX1 exons, implying that cisregulatory elements may also be able to reduce RUNX1 Figure 5. RUNX1 physically interacts with STAT3 to attenuate phosphorylation of STAT3 after cytokine treatment. (a) Co-immunoprecipitation of RUNX1 with STAT3 in HEK293T cells. GFP-tagged FLAGHA-STAT3, RUNX1, or GFP-expressing plasmids were overexpressed in HEK293T. Lysates were co-immunoprecipitated using GFP beads, and western blots were probed with indicated antibodies. (b) Co-immunoprecipitation of endogenous STAT3 with RUNX1 in HEK293T cells. EGFP-tagged RUNX1, or EGFP-expressing plasmids were overexpressed in HEK293T by lipofection. Lysates were co-immunoprecipitated using GFP beads, and western blots were probed with indicated antibodies. (c) Coimmunoprecipitation of RUNX1 with STAT3 in Jurkat cells. Lysates were co-immunoprecipitated with the indicated antibodies. Western blots were probed with the indicated antibodies. Representative blots from three independent experiments are shown. (d) Schematic diagram of mutant constructs of RUNX1 and STAT3. (e and f) Co-immunoprecipitation of RUNX1 mutant constructs with STAT3 (e), and reciprocal coimmunoprecipitation of STAT3 mutant constructs with RUNX1 (f). Lysates were co-immunoprecipitated using GFP beads, and western blots were probed with indicated antibodies. (g) Attenuation of p-STAT3 by RUNX1 mutants. HEK293T were transfected with indicated RUNX1 constructs for 24 h and treated with 50 ng/ml oncostatin-M (OSM) for 30 min. The percentage of p-STAT3-positive cells was determined by Phosflow analysis. Mean ± s.d. of three independent experiments is shown. (h) Interaction of FPD/MM patients-associated RUNX1 mutants with STAT3. Lysates were co-immunoprecipitated using GFP beads, and western blots were probed with indicated antibodies. (i) Attenuation of p-STAT3 by RUNX1 or FPD/ MM patients-associated RUNX1 mutants. HEK293T were transfected with RUNX1, R174Q or Y260X for 24 h and treated with 50 ng/ml OSM for 30 min. The percentage of p-STAT3-positive cells was determined by flow cytometry. Mean ± s.d. of three independent experiments is shown. Asterisks represent significant differences (*Po0.05, **P o0.01, ***Po0.001 and two-tailed Student's t-test).  Figure 6. Peripheral mononuclear cells from FPD patient show G-CSF hypersensitivity in vitro. (a and b) Colony-forming potential of PB mononuclear cells (PBMC) in the presence of increasing amount of G-CSF. Three hundred thousand PBMCs derived from two healthy donors and FPD patient harboring point mutation in Runt domain (RUNX1 +/G143W ) were treated with indicated concentrations of G-CSF. Mean ± s.d. is shown. In b, the difference in size of colony was shown. (c) Schematic diagrams depicting how RUNX1 negatively regulate STAT3 signaling (left). RUNX1 haploinsufficiency (center) and point mutation (right) results in reduced CXCR4 and PIAS3 transcription and physical sequestration of STAT3 by RUNX1. Asterisks represent significant differences (*P o0.05 and two-tailed Student's t-test).
expression. 40 Establishment of new accurate diagnosis methods is warranted. Our study shows that G-CSF hypersensitivity is observed in vitro irrespective of the types of RUNX1 alterations. As granulocyte-macrophage CSF hypersensitivity is also used as a criterion to diagnose juvenile myelomonocytic leukemia, 41 we propose that G-CSF hypersensitivity would serve as a complementary test to detect affected FPD subjects, including cryptic cases.